Tiziana Life Sciences announced positive Phase 2a results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). The trial met its primary endpoint with a significant reduction in microglial activation and showed clinically meaningful fatigue improvements after 12 weeks. Both 50μg and 100μg doses were well tolerated, with no serious adverse events. These results support advancing to a pivotal trial and further FDA discussions.
Tiziana Life Sciences' positive Phase 2a results provide context for health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 00:41 WIB: out of 150 priced US health-sector stocks, 12 rose and 138 fell. Novavax Inc (NVAX) traded at USD 9.40 with a 1-day change of -11.74%, Summit Therapeutics Inc (SMMT) was at USD 14.34 down 11.32%, and Iovance Biotherapeutics Inc (IOVA) closed at USD 7.72 with an 11.26% decline.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
Cenovus Energy is experiencing a widened discount to light oil, reaching $31.70, which will affect its fourth quarter results in fiscal year 2026. Management attributes this discount expansion mainly to temporary freight costs and is sticking to its ...
U.S. spot Bitcoin ETFs experienced net outflows of $430.20 million on November 5, reversing the previous day's inflows of $74.57 million. Six of the twelve funds, including Fidelity’s FBTC and BlackRock’s IBIT, saw significant withdrawals. Total trad...
Macro analyst Roberto Rios predicts Bitcoin will reach $300,000 during the current market cycle, citing unexpected strength since a June low. He explains that the market is factoring in increased money creation by the Federal Reserve and further weak...
